⌘K

Login Start Free

Home/Filings/4/0001968202-24-000072

4//SEC Filing

SING GEORGE L 4

Accession 0001968202-24-000072

CIK 0000872589other

View on SEC.gov Company Profile

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 4:07 PM ET

Size

20.3 KB

Accession

0001968202-24-000072

Insider Transaction Report

Form 4

Period: 2024-02-22

REGENERON PHARMACEUTICALS, INC.REGN

Director

Transactions

Sale
Common Stock
2024-02-22$960.00/sh−1,000$960,000→ 26,349 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-02-23−500→ 6,338 total
Exercise: $413.33Exp: 2025-01-02→ Common Stock (500 underlying)
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Sale
Common Stock
2024-02-22$965.00/sh−1,000$965,000→ 26,349 total
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Exercise/Conversion
Common Stock
2024-02-23$413.33/sh+500$206,665→ 26,849 total
Exercise/Conversion
Common Stock
2024-02-22$413.33/sh+1,000$413,330→ 27,349 total
Sale
Common Stock
2024-02-22$970.00/sh−1,000$970,000→ 26,349 total
Sale
Common Stock
2024-02-23$985.00/sh−500$492,500→ 26,349 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-02-22−3,000→ 6,838 total
Exercise: $413.33Exp: 2025-01-02→ Common Stock (3,000 underlying)

Holdings

Common Stock
(indirect: By Spouse)
400
Common Stock
(indirect: By Spouse)
750
Common Stock
(indirect: By Trust)
1,000

Footnotes (1)

[F1]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

REGENERON PHARMACEUTICALS, INC.

CIK 0000872589

Entity typeother

Related Parties

1

filerCIK 0001225471

Filing Metadata

Form type: 4
Filed: Feb 25, 7:00 PM ET
Accepted: Feb 26, 4:07 PM ET
Size: 20.3 KB

View on SEC.gov